These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

548 related items for PubMed ID: 12687553

  • 21. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age.
    Bracaglia C, Buonuomo PS, Tozzi AE, Pardeo M, Nicolai R, Campana A, Insalaco A, Cortis E, DE Benedetti F.
    J Rheumatol; 2012 Jun; 39(6):1287-90. PubMed ID: 22589254
    [Abstract] [Full Text] [Related]

  • 22. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis.
    Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, Robinson M, Kim J, Barron KS.
    Arthritis Rheum; 2005 Feb 15; 53(1):18-23. PubMed ID: 15696578
    [Abstract] [Full Text] [Related]

  • 23. [Side effects of anti-TNFalpha therapy in juvenile idiopathic arthritis].
    Pontikaki I, Gerloni V, Gattinara M, Luriati A, Salmaso A, De Marco G, Teruzzi B, Valcamonica E, Fantini F.
    Reumatismo; 2006 Feb 15; 58(1):31-8. PubMed ID: 16639486
    [Abstract] [Full Text] [Related]

  • 24. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis.
    De Benedetti F, Meazza C, Vivarelli M, Rossi F, Pistorio A, Lamb R, Lunt M, Thomson W, Ravelli A, Donn R, Martini A, British Paediatric Rheumatology Study Group.
    Arthritis Rheum; 2003 May 15; 48(5):1398-407. PubMed ID: 12746913
    [Abstract] [Full Text] [Related]

  • 25. Serum osteopontin as a predictive marker of responsiveness to methotrexate in juvenile idiopathic arthritis.
    Masi L, Ricci L, Zulian F, Del Monte F, Simonini G, Capannini S, De Martino M, Brandi ML, Falcini F.
    J Rheumatol; 2009 Oct 15; 36(10):2308-13. PubMed ID: 19684155
    [Abstract] [Full Text] [Related]

  • 26. Etanercept treatment improves longitudinal growth in prepubertal children with juvenile idiopathic arthritis.
    Vojvodich PF, Hansen JB, Andersson U, Sävendahl L, Hagelberg S.
    J Rheumatol; 2007 Dec 15; 34(12):2481-5. PubMed ID: 18050366
    [Abstract] [Full Text] [Related]

  • 27. Etanercept Immunex.
    Yung RL.
    Curr Opin Investig Drugs; 2001 Feb 15; 2(2):216-21. PubMed ID: 11816834
    [Abstract] [Full Text] [Related]

  • 28. Etanercept therapy in children with treatment-resistant uveitis.
    Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, Gallagher K, Stout T.
    Arthritis Rheum; 2001 Jun 15; 44(6):1411-5. PubMed ID: 11407702
    [Abstract] [Full Text] [Related]

  • 29. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.
    Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2008 May 15; 58(5):1496-504. PubMed ID: 18438876
    [Abstract] [Full Text] [Related]

  • 30. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis.
    Kimura Y, Pinho P, Walco G, Higgins G, Hummell D, Szer I, Henrickson M, Watcher S, Reiff A.
    J Rheumatol; 2005 May 15; 32(5):935-42. PubMed ID: 15868633
    [Abstract] [Full Text] [Related]

  • 31. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
    Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, Job-Deslandre C, Fautrel B, Le Loët X, Sibilia J, Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP), Club Rhumatismes et Inflammation (CRI).
    Ann Rheum Dis; 2008 Mar 15; 67(3):302-8. PubMed ID: 17947302
    [Abstract] [Full Text] [Related]

  • 32. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
    Woo P, Southwood TR, Prieur AM, Doré CJ, Grainger J, David J, Ryder C, Hasson N, Hall A, Lemelle I.
    Arthritis Rheum; 2000 Aug 15; 43(8):1849-57. PubMed ID: 10943876
    [Abstract] [Full Text] [Related]

  • 33. Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: results of a Canadian multicenter, prospective inception cohort study.
    Oen K, Tucker L, Huber AM, Miettunen P, Scuccimarri R, Campillo S, Cabral DA, Feldman BM, Tse S, Chédeville G, Spiegel L, Schneider R, Lang B, Ellsworth J, Ramsey S, Dancey P, Silverman E, Chetaille AL, Cameron B, Johnson N, Dorval J, Petty RE, Duffy KW, Boire G, Haddad E, Houghton K, Saint-Cyr C, Turvey SE, Benseler S, Cheang M, Yeung RS, Duffy CM.
    Arthritis Rheum; 2009 Aug 15; 61(8):1077-86. PubMed ID: 19644903
    [Abstract] [Full Text] [Related]

  • 34. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
    Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, White B.
    J Rheumatol; 2006 Feb 15; 33(2):234-43. PubMed ID: 16465653
    [Abstract] [Full Text] [Related]

  • 35. Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO.
    Minden K, Niewerth M, Zink A, Seipelt E, Foeldvari I, Girschick H, Ganser G, Horneff G.
    Rheumatology (Oxford); 2012 Aug 15; 51(8):1407-15. PubMed ID: 22447885
    [Abstract] [Full Text] [Related]

  • 36. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    JAMA; 2011 Dec 07; 306(21):2340-7. PubMed ID: 22056397
    [Abstract] [Full Text] [Related]

  • 37. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis.
    Papsdorf V, Horneff G.
    Rheumatology (Oxford); 2011 Jan 07; 50(1):214-21. PubMed ID: 21148155
    [Abstract] [Full Text] [Related]

  • 38. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register.
    Prince FH, de Bekker-Grob EW, Twilt M, van Rossum MA, Hoppenreijs EP, ten Cate R, Koopman-Keemink Y, Gorter SL, Raat H, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2011 Jun 07; 50(6):1131-6. PubMed ID: 21278067
    [Abstract] [Full Text] [Related]

  • 39. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
    Anink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF, ten Cate R, van Rossum MA, van den Berg JM, Dolman KM, Koopman-Keemink Y, Armbrust W, Kamphuis S, van Pelt PA, Gorter SL, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2013 Apr 07; 52(4):712-7. PubMed ID: 23267169
    [Abstract] [Full Text] [Related]

  • 40. Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis.
    Ringold S, Chon Y, Singer NG.
    Arthritis Rheum; 2009 Dec 07; 60(12):3776-83. PubMed ID: 19950286
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.